NCT01808313View on ClinicalTrials.gov

Efficacy Study of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension (PAH)

PHASE3CompletedINTERVENTIONAL
Enrollment

134

Participants

Timeline

Start Date

December 1, 2012

Primary Completion Date

August 15, 2014

Study Completion Date

August 15, 2014

Conditions
Vascular Disease
Interventions
DRUG

ambrisentan

Ambrisentan 5 mg will be administered to eligible subjects for 12 weeks

Trial Locations (12)

100032

GSK Investigational Site, Beijing

100034

GSK Investigational Site, Beijing

100037

GSK Investigational Site, Beijing

100038

GSK Investigational Site, Beijing

130021

GSK Investigational Site, Changchun

150001

GSK Investigational Site, Harbin

200001

GSK Investigational Site, Shanghai

200433

GSK Investigational Site, Shanghai

250012

GSK Investigational Site, Jinan

410008

GSK Investigational Site, Hunan

430022

GSK Investigational Site, Wuhan

710032

GSK Investigational Site, Xi'an

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01808313 - Efficacy Study of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension (PAH) | Biotech Hunter | Biotech Hunter